Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Glipizide
Drug ID BADD_D01024
Description Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure.[T28] Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency.[A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents.[A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Indications and Usage For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.
Marketing Status Prescription; Discontinued
ATC Code A10BB07
DrugBank ID DB01067
KEGG ID D00335
MeSH ID D005913
PubChem ID 3478
TTD Drug ID D0Z4SB
NDC Product Code 0591-0900; 68788-8138; 50090-4297; 43353-369; 53747-047; 68084-295; 68084-112; 68788-0142; 10370-745; 70771-1100; 53002-4460; 68071-4939; 0049-1581; 63629-8181; 70518-2573; 63629-2204; 67296-1267; 16729-139; 63629-1394; 53002-4462; 72789-130; 68382-335; 51407-621; 17373-1060; 16714-896; 68071-4498; 68071-3009; 68071-4857; 50268-361; 70934-300; 59651-270; 0591-0460; 0049-0174; 61919-287; 55700-624; 50090-5040; 70518-2624; 50090-0502; 17373-1061; 71335-0590; 63187-811; 60760-568; 71610-388; 61919-722; 63629-2205; 63629-2203; 42291-430; 0378-1110; 55154-7987; 71335-0036; 70934-391; 70518-0579; 0591-0844; 17337-0230; 49452-3299; 43744-182; 50090-4008; 64980-279; 67544-097; 51655-180; 68645-575; 67544-129; 43353-207; 0591-0461; 68071-4085; 24196-176; 12634-729; 43353-379; 16714-894; 51927-3111; 55289-806; 51655-361; 59651-268; 0615-8407; 16729-140; 70771-1099; 63187-993; 70518-0552; 68071-4124; 50090-0852; 12634-790; 62147-0001; 63629-2202; 68382-336; 71335-0618; 0615-7969; 62147-0400; 58118-0141; 70771-1098; 68084-111; 71335-1042; 60760-745; 0378-1105; 48589-0008; 68788-0141; 71205-041; 42291-429; 66267-099; 12828-0051; 0615-8408; 0591-0845; 61919-476; 60505-0142; 71335-0388; 59651-269; 68382-337; 12780-4680; 55700-585; 51079-811; 68071-4994; 0049-1582; 70518-1848; 42708-109; 71335-1592; 71335-0930; 54752-0054; 50090-0503; 50090-4911; 70934-843; 68645-574; 55289-301; 71335-0851; 0049-0170; 70934-666; 50090-0505; 53002-1111; 71335-2050; 68788-7856; 70934-862; 10370-746; 68071-4643; 38779-0765; 63187-477; 62559-316; 63187-255; 53002-2111; 51655-106; 0049-0178; 72189-070; 71335-1031; 58793-005; 70934-098; 68071-4378; 60760-329; 71610-105; 64980-281; 50090-5377; 51655-337; 71335-1130; 50090-2915; 43063-861; 59762-0542; 50090-4199; 70518-2888; 0904-6637; 50090-5806; 55289-779; 71610-175; 71610-393; 70934-272; 60505-0141; 50090-3069; 60760-165; 59762-0540; 68071-4232; 59762-0541; 51655-810; 63629-5256; 66326-400; 67544-302; 64980-280; 70518-1063; 0615-7968; 16714-895; 63629-1398; 60687-480; 50268-362
Synonyms Glipizide | Glypidizine | Glidiazinamide | Glydiazinamide | Glucotrol | Minidiab | Mindiab | Minodiab | K-4024 | K 4024 | K4024 | Melizide | Ozidia | Glupitel
Chemical Information
Molecular Formula C21H27N5O4S
CAS Registry Number 29094-61-9
SMILES CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HypoglycaemiaCytochrome P450 2C9P11712T1924410208645; 11740344; 8873220
Liver disorderGlycogen synthase kinase-3 betaP49841T709778043894; 11569484; 8408617
Liver disorderSolute carrier family 2, facilitated glucose transporter member 4P14672T676588043894; 11569484; 8408617
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tremor17.01.06.0020.000177%
Unresponsive to stimuli17.02.05.0310.000766%Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria10.01.06.001; 23.04.02.0010.000353%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.0100.000118%
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.0060.000177%
Mental status changes19.07.01.0010.000589%Not Available
Hypoglycaemic seizure05.06.03.002; 17.12.03.015; 14.06.03.0020.000177%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.000177%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000118%
Blood glucose fluctuation13.02.02.0070.000236%Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Bile duct obstruction09.02.02.002--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Urine output increased13.13.03.002--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite08.01.09.028; 14.03.01.0050.000530%
Ill-defined disorder08.01.03.049--Not Available
Drug intolerance08.06.01.0130.000177%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.0100.000118%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000530%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages